Literature DB >> 20511667

Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.

Eva Geissinger1, Petra Sadler, Sabine Roth, Tina Grieb, Bernhard Puppe, Nora Müller, Peter Reimer, Claudia S Vetter-Kauczok, Jörg Wenzel, Irina Bonzheim, Thomas Rüdiger, Hans Konrad Müller-Hermelink, Andreas Rosenwald.   

Abstract

BACKGROUND: CD30(+) T-cell lymphoproliferations comprise a spectrum of clinically heterogeneous entities, including systemic anaplastic large cell lymphomas (ALK(-) and ALK(+)) and primary cutaneous CD30(+) T-cell lymphoproliferative disorders. While all these entities are characterized by proliferation of highly atypical, anaplastic CD30(+) T cells, the expression of T-cell specific antigens in the tumor cells is not consistently detectable. DESIGN AND METHODS: We evaluated biopsies from 19 patients with primary cutaneous CD30(+) lymphoproliferative disorders, 38 with ALK(-) and 33 with ALK(+) systemic anaplastic large cell lymphoma. The biopsies were examined for the expression of T-cell receptorαβ/CD3 complex (CD3γ, δ, ε, ζ), transcription factors regulating T-cell receptor expression (ATF1, ATF2, TCF-1, TCF-1α/LEF-1, Ets1), and molecules of T-cell receptor-associated signaling cascades (Lck, ZAP-70, LAT, bcl-10, Carma1, NFATc1, c-Jun, c-Fos, Syk) using immunohistochemistry.
RESULTS: In comparison to the pattern in 20 peripheral T-cell lymphomas, not otherwise specified, we detected a highly disturbed expression of the T-cell receptor/CD3 complex, TCF-1, TCF-1α/LEF-1, Lck, ZAP-70, LAT, NFATc1, c-Jun, c-Fos and Syk in most of the systemic anaplastic large cell lymphomas. In addition, primary cutaneous CD30(+) lymphoproliferative disorders showed such a similar expression pattern to that of systemic anaplastic large cell lymphomas, that none of the markers we investigated can reliably distinguish between these CD30(+) T-cell lymphoproliferations.
CONCLUSIONS: Severely altered expression of the T-cell receptor/CD3 complex, T-cell receptor-associated transcription factors and signal transduction molecules is a common characteristic of systemic and cutaneous CD30(+) lymphoproliferations, although the clinical behavior of these entities is very different. Since peripheral T-cell lymphomas, not otherwise specified retain the full expression program required for functioning T-cell receptor signaling, the differential expression of a subset of these markers might be of diagnostic utility in distinguishing peripheral T-cell lymphomas, not otherwise specified from the entire group of CD30(+) lymphoproliferations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20511667      PMCID: PMC2948095          DOI: 10.3324/haematol.2009.021428

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  39 in total

1.  Differential regulation by leukotrienes and calcium of Fc gamma receptor-induced phagocytosis and Syk activation in dendritic cells versus macrophages.

Authors:  Claudio Canetti; David M Aronoff; Mun Choe; Nicolas Flamand; Scott Wettlaufer; Galen B Toews; Gwo-Hsiao Chen; Marc Peters-Golden
Journal:  J Leukoc Biol       Date:  2006-03-30       Impact factor: 4.962

Review 2.  CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.

Authors:  Werner Kempf
Journal:  J Cutan Pathol       Date:  2006-02       Impact factor: 1.587

Review 3.  Deciphering the pathway from the TCR to NF-kappaB.

Authors:  R Weil; A Israël
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

Review 4.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

5.  Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas.

Authors:  B Martínez-Delgado; M Cuadros; E Honrado; A Ruiz de la Parte; G Roncador; J Alves; J M Castrillo; C Rivas; J Benítez
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

6.  The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas.

Authors:  Jennifer C Paterson; Sara Tedoldi; Andrew Craxton; Margaret Jones; Martin-Leo Hansmann; Graham Collins; Helen Roberton; Yasodha Natkunam; Stefano Pileri; Elias Campo; Edward A Clark; David Y Mason; Teresa Marafioti
Journal:  Haematologica       Date:  2006-06       Impact factor: 9.941

7.  CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells.

Authors:  Casey W Wright; Julie M Rumble; Colin S Duckett
Journal:  J Biol Chem       Date:  2007-01-29       Impact factor: 5.157

8.  c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.

Authors:  Elias Drakos; Vasiliki Leventaki; Ellen J Schlette; Dan Jones; Pei Lin; L Jeffrey Medeiros; George Z Rassidakis
Journal:  Am J Surg Pathol       Date:  2007-03       Impact factor: 6.394

Review 9.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

10.  Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas.

Authors:  X Mao; G Orchard; R Russell-Jones; S Whittaker
Journal:  Br J Dermatol       Date:  2007-08-24       Impact factor: 9.302

View more
  16 in total

1.  CD30+ lymphoproliferative disorders.

Authors:  Laurence de Leval; Philippe Gaulard
Journal:  Haematologica       Date:  2010-10       Impact factor: 9.941

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis.

Authors:  Jun An; Hiroshi Fujiwara; Koichiro Suemori; Toshiyuki Niiya; Taichi Azuma; Kazushi Tanimoto; Toshiki Ochi; Yoshiki Akatsuka; Junichi Mineno; Hidetoshi Ozawa; Fumihiko Ishikawa; Kiyotaka Kuzushima; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2011-01-13       Impact factor: 2.490

4.  T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy.

Authors:  Tianjiao Wang; Ye Lu; Avery Polk; Pinki Chowdhury; Carlos Murga-Zamalloa; Hiroshi Fujiwara; Koichiro Suemori; Niklas Beyersdorf; Alexandra C Hristov; Megan S Lim; Nathanael G Bailey; Ryan A Wilcox
Journal:  Clin Cancer Res       Date:  2016-10-25       Impact factor: 12.531

5.  CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.

Authors:  Bettina Bisig; Aurélien de Reyniès; Christophe Bonnet; Pierre Sujobert; David S Rickman; Teresa Marafioti; Georges Delsol; Laurence Lamant; Philippe Gaulard; Laurence de Leval
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

6.  Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Dmitriy Abramov; Ilske Oschlies; Martin Zimmermann; Dmitriy Konovalov; Christine Damm-Welk; Wilhelm Wössmann; Wolfram Klapper
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

7.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  Shimin Hu; Zijun Y Xu-Monette; Aarthi Balasubramanyam; Ganiraju C Manyam; Carlo Visco; Alexander Tzankov; Wei-min Liu; Roberto N Miranda; Li Zhang; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Xiaoying Zhao; Jane N Winter; Mingzhi Zhang; Ling Li; Michael B Møller; Miguel A Piris; Yong Li; Ronald S Go; Lin Wu; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-01-23       Impact factor: 22.113

Review 8.  A three-signal model of T-cell lymphoma pathogenesis.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

Review 9.  T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway.

Authors:  Kathrin Warner; Nicole Weit; Giuliano Crispatzu; Joan Admirand; Dan Jones; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

10.  Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas.

Authors:  S M Rodríguez-Pinilla; M E C Sánchez; J Rodríguez; J F García; B Sánchez-Espiridión; L F Lamana; G Sosa; J C Rivero; J Menárguez; I B Gómez; F I Camacho; P R Guillen; C P S Orduña; G Rodríguez; C Barrionuevo; R Franco; M Mollejo; J F Marco; R D de Otazu; M A Piris
Journal:  Blood Cancer J       Date:  2013-04-19       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.